Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Hodgkin's lymphoma

D L Longo1

  • 1Biological Response Modifiers Program, National Cancer Institute, Frederick Cancer Research and Development Center, MD 21702-1201, USA.

Current Opinion in Hematology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial cells require functional FLVCR1a during developmental and adult angiogenesis.

Angiogenesis·2023
Same author

Complete on/off responsive ParaCEST MRI contrast agents for copper and zinc.

Dalton transactions (Cambridge, England : 2003)·2018
Same author

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.

Clinical pharmacology and therapeutics·2016
Same author

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Leukemia·2014
Same author

p52-Independent nuclear translocation of RelB promotes LPS-induced attachment.

Biochemical and biophysical research communications·2009
Same author

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

Leukemia·2007

Lymphoma incidence is rising due to environmental factors. Current research focuses on new treatments for follicular and aggressive lymphomas, improving patient outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Environmental Health

Background:

  • Lymphoma incidence is increasing, linked to environmental factors like occupational exposures and HIV.
  • New clinico-pathologic entities, including mantle cell lymphoma and mucosal-associated lymphatic tissue lymphoma, have been identified.
  • Follicular lymphomas and diffuse aggressive-histology lymphomas remain the most prevalent types.

Purpose of the Study:

  • To review current understanding and treatment strategies for prevalent lymphomas.
  • To highlight advancements in defining new lymphoma subtypes.
  • To discuss ongoing efforts to improve cure rates for localized and advanced lymphomas.

Main Methods:

  • Review of molecular and immunologic studies.
  • Analysis of treatment outcomes for localized and advanced follicular lymphomas.

Related Experiment Videos

  • Evaluation of treatment intensity for aggressive-histology lymphomas.

    • Main Results:

    • Localized follicular lymphomas are curable with radiation therapy.
    • Advanced follicular lymphoma treatment focuses on post-chemotherapy consolidation (interferon, high-dose chemoradiotherapy, immunotherapy).
    • Aggressive-histology lymphoma shows high curability rates ( >85% localized, >50% disseminated) with high-dose intensity therapy.

    Conclusions:

    • Significant progress has been made in defining lymphoma subtypes and improving treatment efficacy.
    • Curability of follicular and aggressive lymphomas is achievable, with ongoing research focused on enhancing outcomes for advanced stages.
    • Environmental factors play a role in lymphoma development, necessitating continued research into prevention and treatment.